Robert Rosenheck, MD
Professor of Psychiatry, Epidemiology and Public Health, and the Child Study Center, Yale Medical School
Dr Rosenheck has disclosed he received research support from Pfizer Pharmaceuticals to analyze CATIE data and has served as a consultant to Otsuka Pharmaceuticals on a long acting injectable antipsychotic. Dr. Balt has reviewed this article and found no evidence of bias in this educational activity.
Are the benefits of atypical antipsychotics based in reality? Dr. Rosenheck explains the stark difference between the SGAs of pharmaceutical myth and what has been proven with actual science.